The 30th Annual Diabetes Day: Therapeutics and Technology is presented by the Cleveland Clinic Department of Endocrinology, Diabetes and Metabolism to provide up-to-date reviews of management strategies and research on the complications of diabetes. The goal of this symposium is to increase practitioners’ competence and clinical performance in treating diabetes and its complications and, ultimately, to improve patient outcomes.
Key topic areas that will be addressed include:
- MASLD, new consensus guidelines
- Tirzepatide cardiac outcomes
- GLP-1 agonist vs SGLT-2 Inhibitors vs Multi-agonist Therapy
- Latest technology in insulin pumps
- Review of therapeutic options to manage both Type 1 and 2 diabetes
- Technology Updates in Pregnancy
- Role of amyloid in pathogenesis of diabetes and dementia
- And much more
Attendees will be able to:
- Identify and critically appraise current and emerging diabetes technologies used during pregnancy, including CGM, automated insulin delivery systems, and remote monitoring, understand the evidence showing how these tools improve maternal glucose control and reduce neonatal risks, and apply practical strategies for choosing and adjusting the right technology for pregnant patients with Type 1, Type 2, or gestational diabetes.
- Describe cardiac outcomes in diabetes management and explain how tirzepatide’s dual incretin mechanism relates to improving cardiometabolic health, understand recent evidence on its effects on major cardiovascular events, and apply this knowledge to treatment decisions by weighing its glucose-lowering, weight-loss, and cardiac benefits for high-risk patients.
- Discuss the effects of GLP-1 agonists on peripheral vascular disease (PVD) with a focus on the STRIDE study and review the pathophysiology of PVD and how to incorporate GLP-1 therapy into clinical practice for patients at risk of PVD, including considerations for dosing and monitoring vascular endpoints.
- Explain congestive heart failure (CHF) in diabetes, explaining the mechanisms linking diabetes and increased risk for congestive heart failure, implementing screening strategies to identify early CHF in patients with diabetes and how to select appropriate therapies, including SGLT-2 inhibitors for the management of CHF in patients with diabetes.
- Describe the scientific rationale for targeting melanin inhibition as a metabolic pathway in Type 2 diabetes and evaluate safety and efficacy findings from the Covalent III trial.
- Explain the role of islet amyloid polypeptide (IAPP) in β-cell dysfunction and its link to cognitive decline, assess implications for prevention and early intervention strategies in dementia risk and review current and emerging interventions that aim to reduce amyloid burden.
Who should attend?
This activity is designed for physicians, diabetes educators, nurses, nurse practitioners, pharmacists, pharmacy technicians, physician assistants, residents and fellows, and other health care professionals who care for patients with diabetes.